Skip to content

US · BCTXZ · BIOTECHNOLOGY

BriaCell Therapeutics Corp. Warrant (BCTXZ) intrinsic value and stock valuation

$0.13as of 2026-11-21 · Mkt cap 163.51K

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

BriaCell Therapeutics Corp. Warrant DCF and intrinsic value

InvestorsCraft values BCTXZ with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from BCTXZ’s statements →

BriaCell Therapeutics Corp. Warrant Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology West Vancouver, BC V7T 2X1 briacell.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$0.00
20112025
Net income
-$-26.63M
20112025
Free cash flow
-$-28.51M
20112025
Total equity
$17.4M
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-27.54M-$-33.33M-$-23.27M-$-15.29M-$-7.11M
Net income-$-26.63M-$-4.79M-$-20.3M-$-26.84M-$-13.82M
EPSd-$-63.4M-$-43.55M-$-203M-$-268.4M-$-460.67M
Operating cash flow-$-28.51M-$-24.13M-$-23.74M-$-12.48M-$-7.75M
Capital expenditure$0.00-$-460K$0.00$0.00$0.00
Free cash flow-$-28.51M-$-24.58M-$-23.74M-$-12.48M-$-7.75M
Total assets$21.7M$5.87M$27.2M$42.6M$58M
Total debt$0.00$0.00$0.00$0.00$30K
Net debt-$-10.53M-$-860K-$-21.25M-$-41.04M-$-57.24M
Total equity$17.4M-$-2.68M-$-3.78M$10.3M$27.7M
Cash and short-term investments$17.9M$860K$21.3M$41M$57.3M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$110K$0.00$0.00$0.00$20K
Gross profit-$-110K$0.00$0.00$0.00-$-20K
Research and development expenses$21.5M$27.2M$15.3M$8.02M$2.02M
Selling, general and administrative expenses$5.9M$6.15M$7.94M$7.27M$4.96M
Other expenses$0.00$0.00$0.00$0.00-$0.00
Operating expenses$27.4M$33.3M$23.3M$15.3M$6.97M
Cost and expenses$27.5M$33.3M$23.3M$15.3M$6.97M
Interest income$120K$290K$890K$140K$0.00
Interest expense$40K$0.00$0.00$0.00$80K
Depreciation and amortization$110K$80K$20K$20K$20K
Ebitda-$-27.43M-$-4.85M-$-23.26M-$-26.82M-$-7.1M
Operating income-$-27.54M-$-33.33M-$-23.27M-$-15.29M-$-7.11M
Total other income/expenses, net$660K$28.4M$2.97M-$-11.55M-$-6.84M
Income before tax-$-26.88M-$-4.93M-$-20.3M-$-26.84M-$-13.82M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-26.63M-$-4.79M-$-20.3M-$-26.84M-$-13.82M
Weighted average shares outstanding$420K$110K$100K$100K$30K
Weighted average diluted shares outstanding$420K$110K$100K$100K$30K
Balance sheet
20252024202320222021
Cash and short-term investments$17.9M$860K$21.3M$41M$57.3M
Net receivables$570K$1.37M$720K$20K$10K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$20M$3.65M$27M$42.4M$57.8M
Property, plant and equipment, net$300K$390K$0.00$0.00$0.00
Goodwill and intangible assets$190K$200K$220K$230K$250K
Long-term investments$530K$420K$0.00$0.00$0.00
Total non-current assets$1.73M$2.22M$220K$230K$250K
Total assets$21.7M$5.87M$27.2M$42.6M$58M
Accounts payable$3.29M$7.17M$1.12M$460K$210K
Short-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$3.99M$7.46M$1.8M$940K$560K
Long-term debt$0.00$0.00$0.00$0.00$30K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$340K$1.1M$29.1M$31.3M$29.8M
Capital lease obligations$0.00$0.00$0.00$0.00$0.00
Total liabilities$4.33M$8.56M$30.9M$32.3M$30.4M
Common stock$102.1M$72.2M$69.6M$65.6M$54.8M
Retained earnings-$-112.14M-$-85.44M-$-80.65M-$-60.35M-$-29.14M
Accumulated other comprehensive income (loss)$28M-$-140K-$-140K-$-140K-$-140K
Total equity$17.4M-$-2.68M-$-3.78M$10.3M$27.7M
Total investments$7.92M$420K$0.00$0.00$0.00
Total debt$0.00$0.00$0.00$0.00$30K
Net debt-$-10.53M-$-860K-$-21.25M-$-41.04M-$-57.24M
Cash flow statement
20252024202320222021
Net income-$-26.63M-$-4.93M-$-20.3M-$-26.84M-$-13.82M
Depreciation and amortization$110K$80K$20K$20K$20K
Stock-based compensation$0.00$1.8M$2.19M$3.07M$1.97M
Change in working capital-$-1.93M$7.05M-$-3.53M-$-390K-$-2.28M
Accounts receivable$740K-$-730K$10K-$-10K$10K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-3.93M$6.05M$660K$250K-$-1.41M
Net cash provided by operating activities-$-28.51M-$-24.13M-$-23.74M-$-12.48M-$-7.75M
Investments in property, plant and equipment$0.00-$-460K$0.00$0.00$0.00
Acquisitions, net$0.00-$-230K$0.00$0.00$0.00
Net cash used for investing activities-$-7.74M-$-680K$0.00$0.00$0.00
Common stock issued$46M$4.42M$4M$0.00$51.6M
Common stock repurchased$0.00$0.00-$-50K-$-10.17M$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$46M$4.42M$3.95M-$-3.74M$65M
Net change in cash$9.67M-$-20.39M-$-19.79M-$-16.23M$57.3M
Cash at end of period$10.5M$860K$21.3M$41M$57.3M
Operating cash flow-$-28.51M-$-24.13M-$-23.74M-$-12.48M-$-7.75M
Capital expenditure$0.00-$-460K$0.00$0.00$0.00
Free cash flow-$-28.51M-$-24.58M-$-23.74M-$-12.48M-$-7.75M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About BriaCell Therapeutics Corp. Warrant

        BriaCell Therapeutics Corp., a biotechnology company based in West Vancouver, Canada, is intensely focused on immuno-oncology, dedicated to engineering novel immunotherapies for cancer treatment. Its flagship compound, Bria-IMT, is a whole-cell cancer vaccine presently in Phase I/IIa clinical development, where it's being evaluated in conjunction with the investigational immunotherapy retifanlimab. The company's pipeline also includes Bria-OTS, a personalized, ready-to-use immunotherapy intended for advanced breast cancer, and BriaDx, a diagnostic tool for determining patient HLA types. BriaCell maintains a non-exclusive clinical trial collaboration with Incyte Corporation to explore the effects of combining various novel clinical candidates. Furthermore, a cooperative research and development agreement with the National Cancer Institute supports preclinical efforts to advance and test Bria-OTS cellular immunotherapy as a cancer therapy.

        CEO
        William V. Williams
        Employees
        16
        Beta
        1.54

        Explore

        Frequently asked questions

        What is the intrinsic value of BriaCell Therapeutics Corp. Warrant (BCTXZ)?

        InvestorsCraft does not currently publish an intrinsic value for BCTXZ. How the IC value is calculated.

        Is BCTXZ undervalued?

        InvestorsCraft does not publish an undervaluation signal for BCTXZ at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.